 |
|
K-State professor developing new strategies for delivery of drugs to fight, treat tuberculosis
August 31, 2005MANHATTAN, KAN. - It has been identified by the World Health Organization as the most dangerous infectious disease, causing more deaths - more than 2 million a year - than any other single infection. Approximately one-third of the world's population is already infected.
"It" is Mycobacterium tuberculosis.
A Kansas State University chemistry professor is seeking to stem the tide in the war against TB. According to the WHO, no new antituberculosis drugs have been marketed during the last 30 years. As such, new strategies are needed to lead to the successful development of antituberculosis therapies.
K-State's Stefan H. Bossmann is researching a new strategy for treatment of the deadly infectious disease using ruthenium-polypyridyl-complexes as antimycobacterial drugs.
Bossmann's research explores unique physical and chemical properties of channel proteins called porins, isolated from Mycobacterium smegmatis and Mycobacterium tuberculosis. He is attempting to understand the working principles of porin channels in natural and artificial environments and he hopes to eventually develop supramolecular model systems to serve as physical models for the biological function of the porin systems.
Bossmann will discuss his research at the American Chemical Society's national meeting and exposition, Aug. 28-Sept. 1, in Washington, D.C. He will give an oral presentation at the conference Tuesday, Aug. 30.
"We have more and more resistant strains developing in Asia and Russia. We're also getting a large number of patients infected with TB immigrating to the United States," Bossmann said.
According to Bossmann, not many antibiotics actually work in treating TB because the disease has been steadily developing resistance to them. This makes new strategies for the delivery of drugs urgently needed, he said.
"It will become extremely difficult to treat cases of TB, in say 10 to 20 years down the road, because new treatment possibilities have not been developed," he said.
A "cocktail" consisting of a variety of drugs must be used to treat TB patients and they must be treated for several months, Bossmann said, but the problem with the conventional treatment is that microbacteria in TB grows slowly, helping it to evade the drugs.
"You might think this is a disadvantage, but it is not," Bossmann said. "The microbacteria has the talent to evade all of those medicines."
Mycobacterium TB has just a few pores in its outer walls which regulate basically all of its metabolics, Bossmann said. When the mycobacteria senses something dangerous like antibiotics, it simply closes the channel.
Bossmann's research is targeting the channels.
"It is the only way for the cells to have an exchange with the outside world as far as we know: to block them and put complexes in which bond irreversibly within those channels, depriving the channels of any possibility to take nutrients in or to discharge waste from its metabolism," he said. "This approach can permanently deactivate TB so that the human immune system can deal with it."
Kansas State University
K-State's Stefan H. Bossmann is researching a new strategy for treatment of the deadly infectious disease using ruthenium-polypyridyl-complexes as antimycobacterial drugs.
Bossmann's research explores unique physical and chemical properties of channel proteins called porins, isolated from Mycobacterium smegmatis and Mycobacterium tuberculosis. He is attempting to understand the working principles of porin channels in natural and artificial environments and he hopes to eventually develop supramolecular model systems to serve as physical models for the biological function of the porin systems.
Bossmann will discuss his research at the American Chemical Society's national meeting and exposition, Aug. 28-Sept. 1, in Washington, D.C. He will give an oral presentation at the conference Tuesday, Aug. 30.
"We have more and more resistant strains developing in Asia and Russia. We're also getting a large number of patients infected with TB immigrating to the United States," Bossmann said.
According to Bossmann, not many antibiotics actually work in treating TB because the disease has been steadily developing resistance to them. This makes new strategies for the delivery of drugs urgently needed, he said.
"It will become extremely difficult to treat cases of TB, in say 10 to 20 years down the road, because new treatment possibilities have not been developed," he said.
A "cocktail" consisting of a variety of drugs must be used to treat TB patients and they must be treated for several months, Bossmann said, but the problem with the conventional treatment is that microbacteria in TB grows slowly, helping it to evade the drugs.
"You might think this is a disadvantage, but it is not," Bossmann said. "The microbacteria has the talent to evade all of those medicines."
Mycobacterium TB has just a few pores in its outer walls which regulate basically all of its metabolics, Bossmann said. When the mycobacteria senses something dangerous like antibiotics, it simply closes the channel.
Bossmann's research is targeting the channels.
"It is the only way for the cells to have an exchange with the outside world as far as we know: to block them and put complexes in which bond irreversibly within those channels, depriving the channels of any possibility to take nutrients in or to discharge waste from its metabolism," he said. "This approach can permanently deactivate TB so that the human immune system can deal with it."
Kansas State University
Tuberculosis Current Events and Tuberculosis News RSSMultiple health concerns surface as winter, vitamin D deficiences arrive
A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."
Study reveals why certain drug combinations backfire
Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.
U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
There's a speed limit to the pace of evolution, Penn biologists say
Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits."
Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.
Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
Scientists take step toward simple and portable tuberculosis tests for developing world
Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years.
More Tuberculosis Current Events and Tuberculosis News Articles
 |
The White Plague: Tuberculosis, Man and Society by Jean Dubos (Author) |
 |
Tuberculosis: A Comprehensive Clinical Reference by H. Simon Schaaf MBChB(Stellenbosch) MMed Paed(Stellenbosch) DCM(Stellenbosch) MD Paed(Stellenbosch) (Editor), Alimuddin I. Zumla BSc MBChB MSc PhD(Lond) FRCP(Lond) FRCP(Edin) (Editor) This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage includes which patient populations face an elevated risk of infection, as well as which therapies are appropriate and how to correctly monitor ongoing treatment so that patients are cured. Properly administer screening tests, interpret their results, and identify manifestations of the disease, with authoritative guidance from expert clinicians from around the world. Discusses screening tests for tuberculosis so you can interpret their results and identify not only common manifestations of the disease, but also those that are comparatively rare-such as tuberculosis in pregnant women. Covers all clinical aspects of tuberculosis... |
 |
The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan (Author) Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of photos. |
 |
Tuberculosis (TUBERCULOSIS ( ROM)) by William N Rom (Editor), Stuart M Garay (Editor) New York Univ., NY. Summarizes the current advances in tuberculosis and discusses the pathology and pathogenesis of the disease. Also covers complications and treatment options. Chapters include history and epidemiology, genomics and microbiology, host response, therapy, and prevention and control. Previous edition: c1996. DNLM: Tuberculosis--Pulmonary. |
 |
Captain of Death: The Story of Tuberculosis by Thomas M. Daniel (Author) The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public health hazard has focused much attention on this ancient disease. This book offers a comprehensive account of the disease from prehistoric times through to the present day, detailing the attempts to eradicate it completely. Its four separate sections (the spread of tuberculosis; its infectious nature; susceptibility to it; and methods of treatment) are linked through the device of presenting... |
 |
The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS (Author), JANE BUIKSTRA (Author) Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders. |
 |
Handbook of Tuberculosis by Stefan H. E. Kaufmann (Editor), Paul van Helden (Editor), Eric Rubin (Editor), Warwick J. Britton (Editor) Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. Dr. Stefan Kaufmann, the Founding Director of the Max Planck Institute for Infection Biology in Berlin and Professor of Microbiology and Immunology at the Charité at the Humboldt University, Berlin, has published more than 600 scientific articles and currently serves as President of the European Federation of Immunological Societies and Chair of the Immunology Division of the American... |
 |
The Return of the White Plague: Global Poverty and the 'New' Tuberculosis by Matthew Gandy (Editor), Alimuddin Zumla (Editor) The dramatic increase since the 1980s in the global prevalence of tuberculosis, a disease destined as recently as thirty years ago for complete eradication, is a story of medical failure. A pandemic whose geography defies simple categorization—it ranges from schools in the UK to prisons in Russia, from refugee camps in central Africa to affluent suburbs in North America—the 'new' tuberculosis is derived from a combination of different developments such as collapsing health-care services, shifting patterns of poverty and inequality, the spread of HIV, and the emergence of virulent drug-resistant strains. This collection provides an international survey of current thought on the spread and control of tuberculosis, covering historical, social, political, and medical aspects. While... |
 |
Tuberculosis (Twenty-First Century Medical Library) by Diane Yancey (Author) One of the deadliest diseases healthcare workers fight today, tuberculosis (often called TB) infects the lungs of one-third of the world's population and kills about 2 million people a year. While scientific breakthroughs brought this bacterial disease under control during the 1960s to the 1980s, it was never completely eliminated. In the early 1990s, TB came back as a serious global threat. Not only has TB now spread to virtually every country on Earth, new strains of TB--which are resistant to the standard antibiotics used to cure it--have appeared. Learn what causes TB, how it spreads, why it is so difficult to treat, and more in this informative volume. |
 |
Historic Tuberculosis Films DVD: History of Pulmonary & Mycobacterium TB & Lung Disease Films Table of Contents: Tuberculosis (1955)11 minutes - This is a fun little film that shows a general history and overview of the effects of tuberculosis on our society. / On the Firing Line (1936) 20 minutes - A fantastic film that has great timeless statistics as well as footage and information about the fight against tuberculosis by the National Tuberculosis Association. / You are the Switchman (1951) 12 minutes running time - A film about noticing the warning signs of cancer and taking appropriate preventative action. You Are the Switchman was a groundbreaking video because it was released two years before the link between smoking cigarettes and cancer was officially out in the open. / City of Hope (1930s) 16 minutes - The Los Angeles Tuberculosis Sanatorium produced this film in the... |
| © 2009 BrightSurf.com |